Analysts Set Glaukos Corporation (NYSE:GKOS) Price Target at $119.69

by · The Cerbat Gem

Glaukos Corporation (NYSE:GKOS – Get Free Report) has received a consensus rating of “Moderate Buy” from the sixteen ratings firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $120.6154.

Several research firms have recently commented on GKOS. Citigroup lifted their price target on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Wells Fargo & Company increased their price target on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. BTIG Research lifted their price target on shares of Glaukos from $104.00 to $116.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Stifel Nicolaus set a $115.00 target price on Glaukos in a research report on Monday, October 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Wednesday, October 8th.

Get Our Latest Research Report on Glaukos

Insider Activity

In other news, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the completion of the transaction, the director owned 34,905 shares in the company, valued at approximately $3,744,259.35. This represents a 12.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Joseph E. Gilliam sold 19,340 shares of Glaukos stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total value of $1,740,600.00. Following the sale, the chief operating officer owned 92,366 shares in the company, valued at $8,312,940. This trade represents a 17.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 24,655 shares of company stock worth $2,310,025. 6.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Glaukos

Institutional investors have recently added to or reduced their stakes in the stock. UMB Bank n.a. grew its position in Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 158 shares during the last quarter. Park Place Capital Corp increased its position in Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 162 shares during the period. REAP Financial Group LLC purchased a new position in shares of Glaukos during the 3rd quarter worth approximately $40,000. AlphaQuest LLC boosted its stake in shares of Glaukos by 5,754.5% in the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 633 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in Glaukos by 16.2% during the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 136 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Trading Up 3.2%

Glaukos stock opened at $115.27 on Wednesday. The stock has a market cap of $6.62 billion, a P/E ratio of -74.85 and a beta of 0.69. The firm’s 50 day moving average price is $92.86 and its 200-day moving average price is $93.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. Glaukos has a 1 year low of $73.16 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS – Get Free Report) last posted its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.11. The firm had revenue of $133.54 million during the quarter, compared to analysts’ expectations of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The business’s revenue was up 38.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.28) EPS. On average, equities analysts predict that Glaukos will post -1.08 earnings per share for the current fiscal year.

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Featured Stories